Affordable Access

Access to the full text

Role of Platinums in Triple-Negative Breast Cancer

Authors
  • Lynce, Filipa1
  • Nunes, Raquel2
  • 1 Harvard Medical School, 450 Brookline Ave YC-1275, Boston, MA, 02215, USA , Boston (United States)
  • 2 Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, Building B, First Floor, 5255 Loughboro Rd, NW, Washington, DC, 20016, USA , Washington (United States)
Type
Published Article
Journal
Current Oncology Reports
Publisher
Springer-Verlag
Publication Date
Mar 22, 2021
Volume
23
Issue
5
Identifiers
DOI: 10.1007/s11912-021-01041-x
Source
Springer Nature
Keywords
License
Yellow

Abstract

Purpose of ReviewPlatinum compounds are used in the treatment of various types of cancer. Here, we review the current role of cisplatin and carboplatin in the treatment of early stage and advanced triple-negative breast cancer (TNBC), and the use of biomarkers in predicting response to platinum therapy.Recent FindingsAddition of carboplatin to a neoadjuvant chemotherapy regimen can result in improvement in the pathological complete response rates. The long-term benefit of the addition of carboplatin to standard chemotherapy regimens remains unproven. Single-agent platinum is an option in the treatment of advanced breast cancer. BRCA1/2 mutations predicted benefit from platinums in advanced, but not early stage breast cancer. There are yet no biomarkers to predict response to platinum in sporadic TNBC.SummaryPlatinum compounds are an option in the treatment of TNBC. Identification of biomarkers to select tumors most likely to derive benefit from these agents is still needed. Ongoing trials are exploring the role of platinum in the adjuvant setting and in combination with other agents, including immune checkpoint inhibitors.

Report this publication

Statistics

Seen <100 times